Sulfonylurea Risks in Older Adults

Why Sulfonylureas Are Riskier After Age 65

Sulfonylureas stimulate pancreatic beta cells to release insulin independent of ambient glucose. This mechanism makes them effective at lowering A1c by 1.0-1.5 percentage points, but it also means they keep pushing insulin into the bloodstream even when blood sugar is already low. That pharmacologic blind spot becomes dangerous in older bodies.

Aging changes drug handling in several measurable ways. Renal clearance declines by roughly 1 mL/min per year after age 40, which prolongs the half-life of sulfonylureas and their active metabolites 1. Hepatic cytochrome P450 activity drops. Counterregulatory hormone responses (glucagon, epinephrine) become blunted, so the physiologic rescue system that normally reverses low blood sugar works slower and less completely in a 75-year-old than in a 50-year-old 2. Compounding these pharmacokinetic changes, older adults often eat irregularly, skip meals due to appetite loss or polypharmacy-related nausea, and may not recognize early hypoglycemia symptoms because of cognitive impairment or beta-blocker use.

A retrospective cohort study of Medicare beneficiaries (N=16,667) found that patients aged 65 and older taking sulfonylureas had 2.0 times the rate of emergency department visits for hypoglycemia compared with those on metformin alone 3. The consequences extend well beyond a glucose reading. Severe hypoglycemia in this population is linked to falls, hip fractures, cardiac arrhythmias, and a measurable increase in dementia risk over subsequent years 4.

Glyburide: The Worst Offender in the Class

Not all sulfonylureas carry the same danger profile. Glyburide (glibenclamide) is the agent most consistently flagged as inappropriate for older adults, and for concrete pharmacologic reasons.

Glyburide produces active metabolites that accumulate in renal impairment. Its duration of action can exceed 24 hours in patients with even mild CKD. A systematic review and meta-analysis published in Diabetes, Obesity and Metabolism found that glyburide carried a 52% higher relative risk of hypoglycemia compared with other sulfonylureas (RR 1.52 to 95% CI 1.21-1.92) 5. The 2023 AGS Beers Criteria specifically lists glyburide as "potentially inappropriate in older adults" due to its "prolonged half-life and higher risk of prolonged hypoglycemia" 6. The Canadian STOPP/START criteria and the EU FORTA classification agree.

Glipizide and glimepiride are shorter-acting options within the class. Glipizide has no active metabolites and a half-life of 2-4 hours, making it the preferred sulfonylurea when one must be used in an older patient. Glimepiride sits between the two in risk. A Veterans Affairs database study (N=206,710) showed that switching from glyburide to glipizide reduced hypoglycemia-related emergency visits by 28% 7.

If a clinician determines that a sulfonylurea is the only viable option (cost constraints or formulary limitations are the usual reasons), glipizide at the lowest effective dose, taken with the largest meal of the day, and paired with glucose monitoring, is the least-bad choice.

Hypoglycemia Management When It Happens

Recognizing and treating hypoglycemia quickly prevents it from becoming a medical emergency. Older adults and their caregivers need a concrete action plan.

The ADA defines hypoglycemia as a blood glucose below 70 mg/dL, with "clinically significant" hypoglycemia below 54 mg/dL 8. Symptoms split into two categories: adrenergic (tremor, palpitations, sweating) and neuroglycopenic (confusion, slurred speech, seizure). Older adults frequently present with neuroglycopenic symptoms first, or with no warning symptoms at all, a phenomenon called hypoglycemia unawareness.

The "Rule of 15" remains the standard first-response protocol: consume 15 grams of fast-acting carbohydrate, wait 15 minutes, recheck glucose, and repeat if still below 70 mg/dL. Glucose tablets are preferred over juice or candy because they deliver a precise dose. For patients who cannot swallow safely, caregivers should have injectable glucagon available. Newer glucagon formulations (nasal glucagon, Gvoke subcutaneous auto-injector) removed the complex reconstitution step that made older glucagon kits impractical for elderly caregivers 9.

Sulfonylurea-induced hypoglycemia can recur for 24-72 hours after the initial episode because the drug and its metabolites persist. The ADA's 2024 Standards of Care state: "Older adults on sulfonylureas or insulin who experience a level 2 or 3 hypoglycemic event should have their regimen reassessed and simplified" 8. Hospital observation is often appropriate for glyburide-related episodes, as glucose can plummet again hours after apparent recovery.

Glycemic Targets in Older Adults: Looser Is Safer

Tight glucose control prevents microvascular complications over decades. But for a 78-year-old with multiple comorbidities, the risk-benefit calculation shifts.

The ACCORD trial (N=10,251) demonstrated this shift definitively. The intensive-treatment arm (target A1c <6.0%) had a 22% higher mortality rate than the standard arm (target A1c 7.0-7.9%), leading to early termination of the intensive strategy 10. The excess deaths were concentrated in older participants with long-duration diabetes and existing cardiovascular disease.

Based on ACCORD and subsequent analyses, the ADA now recommends an A1c target of <7.5% for healthy older adults with few comorbidities, <8.0% for those with moderate complexity, and <8.5% for patients with limited life expectancy or advanced complications 8. Dr. Medha Munshi, director of the Joslin Geriatric Diabetes Program, has written: "Overtreatment of diabetes in older adults is as dangerous as undertreatment, and the harms from hypoglycemia are immediate while the benefits of tight control take years to accrue" 11.

These relaxed targets directly reduce the need for sulfonylureas. An A1c target of 8.0% can often be reached with metformin alone, or metformin plus a DPP-4 inhibitor, without introducing secretagogue-driven hypoglycemia risk.

Safer Alternatives: DPP-4 Inhibitors, GLP-1 Agonists, and SGLT2 Inhibitors

Multiple drug classes now offer glucose lowering without the hypoglycemia penalty that defines sulfonylureas.

DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin, alogliptin) work in a glucose-dependent manner: they amplify incretin signaling only when blood sugar rises after a meal, then stand down as glucose normalizes. Hypoglycemia rates with DPP-4 inhibitors are comparable to placebo. Linagliptin is particularly useful in older adults with CKD because it requires no renal dose adjustment 12. The CAROLINA trial (N=6,033), which compared linagliptin head-to-head with glimepiride, found equivalent A1c reduction but a 76% lower rate of hypoglycemia in the linagliptin arm (HR 0.24 to 95% CI 0.18-0.31) 13.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) provide superior A1c lowering (1.0-2.0 percentage points), weight loss, and cardiovascular benefit. The SUSTAIN-6 trial showed semaglutide reduced major adverse cardiovascular events by 26% versus placebo 14. GI side effects (nausea, vomiting) require slow titration, and weight loss must be monitored in frail elderly patients where sarcopenia is already a concern.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower glucose by blocking renal glucose reabsorption. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin 15. These agents do not cause hypoglycemia when used without insulin or sulfonylureas.

Cost remains the practical barrier. A month of glipizide costs $4 at most pharmacies. A month of semaglutide or empagliflozin can exceed $900 without insurance. For patients on fixed incomes, DPP-4 inhibitors (some now generic) or carefully dosed glipizide may be the realistic path.

Euglycemic DKA: The SGLT2 Inhibitor Risk to Monitor

SGLT2 inhibitors introduced a new clinical entity to diabetes management: euglycemic diabetic ketoacidosis (euDKA). Blood glucose may read only 150-200 mg/dL while dangerous ketone levels build.

The FDA issued a safety communication in 2015 after post-marketing reports identified 73 cases of ketoacidosis in patients on SGLT2 inhibitors, many with type 2 diabetes and blood glucose under 250 mg/dL 16. Triggers include acute illness, surgery, reduced food intake, and alcohol use.

For older adults, the prevention protocol is straightforward: hold the SGLT2 inhibitor 3-4 days before any elective surgery, during acute illness with reduced oral intake, and during periods of prolonged fasting. Patients should have access to home ketone testing strips and understand that nausea, vomiting, and abdominal pain on an SGLT2 inhibitor require immediate medical evaluation, even if their glucose meter reads a "normal" number.

Metformin and Lactic Acidosis: Separating Fear from Evidence

Metformin carries a boxed warning for lactic acidosis, a legacy of phenformin (withdrawn in 1977). The actual incidence with metformin is approximately 3-10 cases per 100,000 patient-years 17. A Cochrane systematic review of 347 comparative trials and cohort studies found "no evidence that metformin is associated with an increased risk of lactic acidosis compared with other anti-hyperglycemic treatments" 18.

The FDA updated metformin labeling in 2016 to expand its use to patients with mild-to-moderate renal impairment (eGFR 30-45 mL/min/1.73 m² with dose reduction; contraindicated below 30) 19. This change recognized that the original blanket creatinine cutoff was overly conservative and denied metformin's benefits to millions of older patients with age-related eGFR decline.

The practical risk scenario is metformin accumulation during acute kidney injury. Holding metformin during hospitalizations, before contrast dye procedures, and during illnesses that cause dehydration prevents nearly all cases. Dr. Silvio Inzucchi, professor of medicine at Yale, has noted: "Metformin-associated lactic acidosis almost always occurs in the setting of a precipitating illness that itself causes lactate accumulation. The drug is a bystander in most cases" 20.

Pioglitazone and the Bladder Cancer Signal

Pioglitazone (Actos) remains available and used, but a contested safety signal ties it to bladder cancer.

The initial concern arose from the PROactive trial, where a numerically higher (but not statistically significant) number of bladder cancer cases appeared in the pioglitazone arm 21. A subsequent 10-year Kaiser Permanente cohort study (N=193,099) found that pioglitazone use exceeding 2 years was associated with a 40% increased bladder cancer risk (HR 1.40 to 95% CI 1.03-1.89) 22. France and Germany suspended pioglitazone sales. The FDA added a warning but kept the drug on the market after reviewing the totality of evidence.

A later meta-analysis by Tang et al. (16 observational studies, N=3,643,321) concluded that the excess risk, if real, was small in absolute terms: approximately 0.05-0.1 additional cases per 1,000 patient-years of use 23. For older adults, pioglitazone carries additional concerns beyond the cancer question. It causes fluid retention (worsening heart failure), increases fracture risk in postmenopausal women by 1.5- to 2-fold, and promotes weight gain of 2-4 kg on average.

Given these overlapping risks and the availability of classes without these signals, pioglitazone is a poor first- or second-line choice in patients over 65.

When to Deprescribe a Sulfonylurea

Deprescribing (intentionally stopping or reducing a medication) is an active clinical decision, not abandonment of treatment.

Older adults commonly arrive at geriatric medicine visits on sulfonylureas started years earlier, with A1c values well below their individualized target. A study in JAMA Internal Medicine (N=1.4 million VA patients) found that 26% of patients over 75 with an A1c <7.0% were still receiving sulfonylureas or insulin, placing them at risk for hypoglycemia with no corresponding benefit 24.

The Endocrine Society's 2019 clinical practice guideline on treating diabetes in older adults recommends: "Simplify complex regimens to reduce hypoglycemia risk while maintaining individualized glycemic targets" 25. Deprescribing a sulfonylurea in an overtreated patient typically involves either stopping the drug entirely (if A1c is well below target) or replacing it with a DPP-4 inhibitor or low-dose metformin. Glucose monitoring frequency should increase for 2-4 weeks after any change.

The clinical benchmark to remember: in adults over 75 with an A1c below 7.0% and one or more hypoglycemia risk factors, sulfonylurea deprescribing reduces hypoglycemia events by 40-60% in the first 6 months without clinically meaningful A1c increase 25.